Evidence map›Paper›PMID 35187866›Full record

Observational studyInternational journal of rheumatic diseases2022

Treatment pattern, satisfaction, and productivity loss of patients with ankylosing spondylitis treated with tumor necrosis factor inhibitors in Korea: A multicenter cross-sectional observational study.

Sang-Hoon Lee, Yong-Gil Kim, Seung-Geun Lee, Soo Hyun Lee, Young-Joo Kim, Ja-Young Jeon, Joo-Young Jo, Hyun-Jeong Yoo, Juneyoung Lee, Tae-Hwan Kim

Open access · greenAbstract readMulticenter StudyObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in International journal of rheumatic diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Observational
  3. Article
  4. Observational
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Sang-Hoon LeeDepartment of Rheumatology, Hospital at Gangdong, Kyung Hee University, Seoul, Korea.
Yong-Gil KimDepartment of Rheumatology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0002-8029-7355
Seung-Geun LeeDepartment of Rheumatology, Pusan National University Hospital, Pusan, Korea.ORCID https://orcid.org/0000-0002-5205-3978
Soo Hyun LeeDivision of Medical, Pfizer Biopharmaceuticals Group, Pfizer Pharmaceuticals Korea Limited, Seoul, Korea.
Young-Joo KimDivision of Medical, Pfizer Biopharmaceuticals Group, Pfizer Pharmaceuticals Korea Limited, Seoul, Korea.
Ja-Young JeonDivision of Medical, Pfizer Biopharmaceuticals Group, Pfizer Pharmaceuticals Korea Limited, Seoul, Korea.
Joo-Young JoDivision of Medical, Pfizer Biopharmaceuticals Group, Pfizer Pharmaceuticals Korea Limited, Seoul, Korea.
Hyun-Jeong YooDivision of Medical, Pfizer Biopharmaceuticals Group, Pfizer Pharmaceuticals Korea Limited, Seoul, Korea.
Juneyoung LeeDepartment of Biostatistics, College of Medicine, Korea University, Seoul, Korea.
Tae-Hwan KimDepartment of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea.ORCID https://orcid.org/0000-0002-3542-2276
Korea Pharma (South Korea) · KRUniversity of Ulsan · KRHanyang University Seoul Hospital · KRKorea University · JP

Funding

Pfizer Korea Inc B1801402
6 · The paper itself

Abstract

aimTo provide in-depth understanding of real-world tumor necrosis factor inhibitor (TNFi) treatment patterns in patients with ankylosing spondylitis (AS) and treatment satisfaction, productivity loss, and associated factors.

methodsThis was a multicenter observational hybrid retrospective chart review and cross-sectional survey study. Disease activity and physical functioning were measured using the Bath AS Disease Activity Index and Bath AS Functional Index, respectively. Treatment satisfaction was determined with the Treatment Satisfaction Questionnaire for Medication (TSQM). Productivity loss was evaluated using the Korean version of the World Health Organization-Health and Work Performance Questionnaire.

resultsA total of 497 patients were enrolled (mean age 40.3 years, 85.3% male, mean AS duration 10 years). The mean duration of TNFi treatment was 6.2 years. Among the four TNFi considered, adalimumab (39.6%) and etanercept (23.5%) were most commonly used at study enrollment. The TSQM convenience domain score was lower than scores in the effectiveness, adverse effects, and global satisfaction domains. Subcutaneous syringe-type injection and intravenous injection were associated with lower patient convenience satisfaction than subcutaneous pen-type injection. Increased costs of lost productivity time were associated with female sex, unemployed status, and higher disease activity.

conclusionsThe most frequently prescribed TNFi was adalimumab, followed by etanercept. Etanercept was used for the longest duration. More convenient treatment options may enhance overall treatment satisfaction. Considerable loss in productivity due to AS was observed in this study. To reflect patients' perspectives, further attention should be paid to factors associated with treatment satisfaction and productivity loss when selecting treatment options.

Indexed as

Antirheumatic AgentsSpondylitis, AnkylosingAdalimumabAdultCross-Sectional StudiesEtanerceptFemaleHumansInfliximabMalePatient SatisfactionPersonal SatisfactionRepublic of KoreaRetrospective StudiesTreatment OutcomeTumor Necrosis Factor-alphaAdalimumabAntirheumatic AgentsEtanerceptInfliximabTumor Necrosis Factor-alphaTumor Necrosis Factor Inhibitorsankylosing spondylitispatient satisfactionproductivity losstreatment patterntumor necrosis factor inhibitor

Identifiers

PMID35187866
PMCPMC9303183
OpenAlexW4212950167

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.